WCLC 2025 - Posters & ePosters-P1.11.37 Impact of Immunotherapy on Overall Survival in Advanced Non-Small Cell Lung Cancer: A Real-World Evidence Analysis

P1.11.37 Impact of Immunotherapy on Overall Survival in Advanced Non-Small Cell Lung Cancer: A Real-World Evidence Analysis

Back to course

Pdf Summary

A retrospective real-world study by the Spanish Lung Cancer Group evaluated the impact of immunotherapy versus chemotherapy on survival in 6,483 patients with advanced non-small cell lung cancer (NSCLC). Among these, 2,803 patients received immunotherapy and 3,680 received chemotherapy alone. Baseline characteristics were balanced between groups, with a median age of 64 years, 75% males, and 90% being current or former smokers.<br /><br />Key findings showed that immunotherapy significantly improved overall survival (OS) compared to chemotherapy, with a median OS of 16.3 months versus 10.1 months (hazard ratio [HR] 0.69, 95% CI 0.64-0.73; p<0.001). The 12- and 24-month OS rates were also higher in the immunotherapy group (60.7% and 36.3%, respectively) than in the chemotherapy group (43.5% and 23.7%). Progression-free survival (PFS) showed a modest benefit with immunotherapy (median 9.1 vs. 7.4 months; HR 0.94; p=0.053).<br /><br />Univariate analysis identified poor prognostic factors common to both groups, including ECOG performance status (PS) of 1, bone and liver metastases, multiple metastatic sites, and comorbidities. Gender and age affected prognosis only in the chemotherapy cohort. Treatment response strongly predicted survival outcomes, with complete responses linked to the best prognosis in both groups.<br /><br />This large real-world evidence confirms that first-line immunotherapy offers clinically meaningful survival benefits over chemotherapy in advanced NSCLC. The findings support immunotherapy’s role in improving patient outcomes, highlighting its importance since its initial approval in 2016. The data also emphasize the prognostic relevance of patient characteristics and treatment response, aiding in personalized treatment decisions.<br /><br />For further inquiries, contact Dr. Enric Carcereny at ecarcereny@iconcologia.net.

Asset Subtitle

Enric Carcereny

Meta Tag

Speaker Enric Carcereny

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

immunotherapy

chemotherapy

non-small cell lung cancer

NSCLC

overall survival

progression-free survival

real-world study

prognostic factors

treatment response

Spanish Lung Cancer Group